DIF-1 inhibits tumor growth in vivo reducing phosphorylation of GSK-3β and expressions of cyclin D1 and TCF7L2 in cancer model mice

• Published in: Biochemical pharmacology Vol. 89; no. 3; pp. 340 - 348
• Main Authors: Takahashi-Yanaga, Fumi, Yoshihara, Tatsuya, Jingushi, Kentaro, Igawa, Kazuhiro, Tomooka, Katsuhiko, Watanabe, Yutaka, Morimoto, Sachio, Nakatsu, Yoshimichi, Tsuzuki, Teruhisa, Nakabeppu, Yusaku, Sasaguri, Toshiyuki
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.06.2014
• Subjects: Animals; Antineoplastic Agents, Phytogenic - therapeutic use; Cyclin D1 - genetics; Cyclin D1 - metabolism; DIF-1; DNA Glycosylases - genetics; DNA Glycosylases - metabolism; Egr-1; Gene Expression Regulation, Neoplastic - drug effects; Glycogen Synthase Kinase 3 - genetics; Glycogen Synthase Kinase 3 - metabolism; Glycogen Synthase Kinase 3 beta; GSK-3β; Hexanones - therapeutic use; Mice; Mice, Knockout; Neoplasms, Experimental - drug therapy; Neoplasms, Experimental - metabolism; Oxidative Stress; Phosphorylation; TCF7L2; Transcription Factor 7-Like 2 Protein - genetics; Transcription Factor 7-Like 2 Protein - metabolism; Wnt/β-catenin signaling pathway; Egr-1; TCF7L2; GSK-3β; Wnt/β-catenin signaling pathway; DIF-1

We reported that differentiation-inducing factor-1 (DIF-1), synthesized by Dictyostelium discoideum, inhibited proliferation of various tumor cell lines in vitro by suppressing the Wnt/β-catenin signaling pathway. However, it remained unexplored whether DIF-1 also inhibits tumor growth in vivo. In t...